A chemical compound is provided according to general formula (1): ##STR00001##

A chemical compound is provided according to general formula (1): ##STR00001##

The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.

The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.

A chemical compound is provided according to general formula (1):

##STR00001##

The present invention provides a urea peptidomimetic boronic compound and pharmaceutical compositions thereof, their preparative methods and uses. The compounds are represented by the following formula (I). ##STR00001##

The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.

The present invention is related to a product for the resolution of racemic mixtures in which various separation processes of a salt composed of a PEGylated resolving agent and an enantiomer in a racemic mixture is utilized. Separation can be caused by temperature-dependent phase transformation of the said salt pair in aqueous or organic media as well as other methods used is separation of PEG such as salting out (e.g. addition of ammonium sulfate). The first cycle of racemic resolution by this method was shown to afford 85% optically pure amino acid from a 50:50 mixture of racemic L,D-amino acids esters. An additional cycle improved optical purity up to 95%.

The present invention is related to a product for the resolution of racemic mixtures in which various separation processes of a salt composed of a PEGylated resolving agent and an enantiomer in a racemic mixture is utilized. Separation can be caused by temperature-dependent phase transformation of the said salt pair in aqueous or organic media as well as other methods used is separation of PEG such as salting out (e.g. addition of ammonium sulfate). The first cycle of racemic resolution by this method was shown to afford 85% optically pure amino acid from a 50:50 mixture of racemic L,D-amino acids esters. An additional cycle improved optical purity up to 95%.

The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.